MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
INKT Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
MiNK Therapeutics, Inc.NASDAQ: INKT
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin not reported for Q1 FY2026
Sources:Income StatementText generated from reported figures; not investment advice.
Net Margin history
Percent of revenue · from the income statement
No Net Margin data reported for this period type.
Net Margin vs competitors
How INKT compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 6.1% | +109941.4 pp | — | |
| LTM Jun 2026 | -164.8% | — | — | |
| LTM Mar 2026 | -1070.3% | — | — | |
| LTM Mar 2026 | -18297.5% | -30712.4 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
OSTXOS Therapies Incorporated | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding INKT) | -617.5% | +39614.5 pp | — | |
Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| Gross Profit | (77.96K) | (121.75K) | (204.62K) | (215.44K) | (181.75K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.97M | 23.12M | 15.49M | 6.34M | 5.76B |
| Selling, General & Admin | 4.56M | 7.71M | 7.43M | 4.1M | 6.73B |
| Operating Expenses | 18.53M | 30.83M | 22.72M | 10.43M | 12.31M |
| Depreciation & Amortization | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| EBITDA | (27.7M) | (27.87M) | (22.25M) | (10.57M) | (12.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.61M) | (30.95M) | (22.92M) | (10.65M) | (12.49M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.43K | 253.32K | 463.26K | 172.57K | 180.25K |
| Interest Expense | 2.43M | 253.32K | 0 | 0 | 0 |
| Other Income / Expenses | (11.61M) | 2.96M | 463.25K | (134.56K) | (6.96K) |
| Income Before Tax | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.03) | (8.31) | (6.54) | (2.90) | (2.93) |
| EPS (Diluted) | (9.03) | (8.31) | (6.54) | (2.80) | (2.93) |
| Weighted Avg Shares | 3.35M | 3.37M | 3.44M | 3.74M | 4.27M |
| Weighted Avg Shares (Diluted) | 3.35M | 3.37M | 3.44M | 3.86M | 4.27M |
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.